Mednet Logo
CommunityMedical Oncology

How do you treat SNUC?

Do you prefer upfront cisplatin/etoposide for 2 cycles, then 50 Gy with ENI, then resection, or induction chemo followed by definitive chemoradiation? What is the best data supporting the general approach to this?
5 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Florida
Answered on

There’s no standard treatment.

Suitable for gross total resection: surgery and postop RT and concomitant chemo.
Not suitable for GTR: chemo RT or induction chemo and reevaluate for surgery and postop RT chemo.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · West Virginia University
Answered on

A recent Chinese meta-analysis of 17 studies and about 250 patients showed best results with concurrent chemoRT with a 42% 5-year OS. Induction chemo was of potential benefit in patients who could/wanted to have surgery as an insufficient response to IC was "salvaged" by surgery. In many who don't w...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Medical University of South Carolina (Charleston)
Answered on

We most often treat per MDACC induction chemo followed by a definitive CRT retrospective paper. Often these are locally advanced and of course, distant recurrence risk is high. In the few situations where the tumor has no intracranial or orbital extension and is deemed T1/T2 or small T3, we do defin...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Texas MD Anderson Cancer Center
Answered on

IC is controversial for many HN sites. However, for SNUC, one of the benefits (theoretically) is the cytoreduction allows for minimizing radiation to the brain and optics which is one of the major challenges of this disease.

While the approach hasn't changed much, small studies also suggest a spectr...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on

Because of its aggressive biologic behavior, with a propensity to early invasion (40% to 50%) of vital structures, in addition to its high risk of distant metastasis (20% to 30%), sinonasal undifferentiated carcinoma poses a unique therapeutic challenge. Most published studies report the outcomes of...

Join for free or sign in to see the full answer